Biomarkers /
CARM1
Overview
CARM1 is altered in 0.93% of all cancers with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CARM1 are CARM1 Mutation (0.60%), CARM1 Amplification (0.42%), CARM1 Loss (0.10%), CARM1 R419W (0.02%), and CARM1 A590T (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.